Skip to Main Content

More of the cancer patients who received CRISPR Therapeutics’ experimental, off-the-shelf CAR-T cell therapy showed complete remissions compared to the drug’s initial study results, according to a company update Tuesday.  Some of the remissions are lasting six months or more, an important measure of durability.

In the CRISPR Therapeutics study, which remains preliminary, 24 adult patients with advanced B-cell lymphoma were injected with escalating doses of CTX110. Fourteen patients, or 58%, responded to treatment. Nine patients, or 38%, had complete responses, meaning tumor cells were no longer detectable.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment